Strategic Planning Group LLC Has $354,000 Stock Position in Eli Lilly and Company $LLY

Key Points

• Strategic Planning Group LLC significantly reduced its holdings in Eli Lilly and Company by 93.9% during the second quarter, now owning only 453 shares worth $354,000.
• Several institutional investors, including PNC Financial Services and GAMMA Investing LLC, have greatly increased their stakes in Eli Lilly during the same period, highlighting strong investment interest.
• Eli Lilly recently reported quarterly earnings of $6.31 EPS, surpassing estimates and showing a 37.6% increase in revenue compared to last year.

Strategic Planning Group LLC reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 93.9% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 453 shares of the company's stock after selling 7,018 shares during the period. Strategic Planning Group LLC's holdings in Eli Lilly and Company were worth $354,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. PNC Financial Services Group Inc. raised its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. grew its stake in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares in the last quarter. GAMMA Investing LLC lifted its position in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after acquiring an additional 81,587 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock valued at $4,808,443,000 after purchasing an additional 682,203 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.4%

Shares of LLY stock traded up $3.33 during trading hours on Monday, reaching $755.32. 2,524,436 shares of the stock traded hands, compared to its average volume of 3,388,311. The firm has a market capitalization of $714.88 billion, a PE ratio of 49.37, a PEG ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.30. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business has a fifty day moving average price of $737.49 and a 200 day moving average price of $769.01.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insiders Place Their Bets

In other news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. 0.14% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.